RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has scheduled a conference call and webinar on Monday, March 10, 2025, at 8:00 a.m. ET to present topline results from its Launch-HTN and Advance-HTN pivotal trials. These studies evaluate lorundrostat, a highly selective aldosterone inhibitor, for its potential to treat uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).
The Launch-HTN trial investigates the safety and efficacy of lorundrostat as an add-on therapy for patients managing uHTN or rHTN while on two to five antihypertensive medications. Similarly, the Advance-HTN trial examines lorundrostat’s effectiveness in combination with a standardized treatment regimen of two or three antihypertensive medications.
Participants can join the event via a domestic call at 1-877-704-4453 or internationally at 1-201-389-0920. A live webcast will also be available on the “News & Events” page of the company’s Investor Relations section.
This announcement marks a critical step for Mineralys Therapeutics as it advances the development of lorundrostat, aiming to address the challenges of hypertension management for patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.